A phase III FZOCUS-2 trial demonstrated a significant improvement in PFS with the utility of fluzoparib for maintenance therapy in platinum-sensitive, relapsed ovarian cancer patients, regardless of BRCA1/2 status.50 This evidence concerns the gene BRCA1 and ovarian cancer.